The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-10. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
===== MeSH D08.811.913.817 – sulfur group transferases (EC 2.8) ===== MeSH D08.811.913.817.200 – coenzyme a-transferases MeSH D08.811.913.817.400 – sulfotransferases MeSH D08.811.913.817.400.300 – aryl sulfotransferase MeSH D08.811.913.817.500 – sulfurtransferases MeSH D08.811.913.817.500.500 – thiosulfate sulfurtransferase
Hong Kong is home to a wide range of museums, galleries, and cultural institutions, and is regarded as one of Asia's leading centres for art, heritage, and visual culture. Major cultural development in the city has taken place in the West Kowloon Cultural District, a large arts and museum quarter on reclaimed land in Kowloon. Its best-known institutions include M+, a museum of visual culture focused on 20th and 21st century art, design, architecture, and moving image, and the Hong Kong Palace Museum, which displays Chinese artworks and artifacts. Apart from West Kowloon, Hong Kong has many additional museums across the territory. The Hong Kong Museum of Art in Tsim Sha Tsui houses collections of Chinese antiquities, calligraphy, painting, and Hong Kong art. The Hong Kong Heritage Museum in Sha Tin focuses on history, art, and local popular culture, with exhibitions on Cantonese opera, film, and design. The Hong Kong Museum of History presents the development of Hong Kong from prehistoric times to the present, while the Hong Kong Science Museum and Hong Kong Space Museum are among the city's main public institutions devoted to science and education. Tai Kwun, a former police station and prison compound in Central, has been revitalised as a centre for heritage and contemporary art, and hosts exhibitions, performances, and public programmes.
=== Absorbance for non-scattering samples === Within a homogeneous medium such as a solution, there is no scattering. In this case, researched extensively by August Beer, the concentration of the absorbing species follows the same linear contribution to absorbance as the path-length. Additionally, the contributions of individual absorbing species are additive. This is a very favorable situation, and made absorbance an absorption metric far preferable to absorption fraction (absorptance). This is the case for which the term "absorbance" was first used. A common expression of the Beer's law relates the attenuation of light in a material as
== Reactions == The entire process converts two amino groups, one from NH+4 and one from aspartate, and a carbon atom from HCO−3, to the relatively nontoxic excretion product urea. This occurs at the cost of four "high-energy" phosphate bonds (3 ATP hydrolyzed to 2 ADP and one AMP). The conversion from ammonia to urea happens in five main steps. The first is needed for ammonia to enter the cycle and the following four are all a part of the cycle itself. To enter the cycle, ammonia is converted to carbamoyl phosphate. The urea cycle consists of four enzymatic reactions: one mitochondrial and three cytosolic. This uses 6 enzymes.
Sources: en.wikipedia.org
=== Biofilm formation === The ability to adhere to medical devices and subsequently form biofilms is a major virulence factor associated with S. haemolyticus. Biofilm formation increases antibiotic resistance and often leads to persistent infections. S. haemolyticus biofilms are not polysaccharide intercellular adhesin (PIA) dependent, and the lack of the ica operon (the gene cluster that encodes the production of PIA) can be used to distinguish S. haemolyticus isolates from other CoNS species. Biofilm formation is influenced by a variety of factors including carbohydrates, proteins, and extracellular DNA. Detachment assays with NaIO4, proteinase K, or DNase result in 38%, 98%, and 100% detachment, respectively. The high level of detachment associated with DNase treatment has led several authors to suggest a cell-to-surface and/or cell-to-cell adhesion function for extracellular DNA. Biofilm formation also appears to be influenced by the presence of glucose and NaCl. Biofilm formation is enhanced when cultivated in TSB with 1% glucose and decreased when cultivated in TSB with 3% NaCl. The production of a capsular polysaccharide decreases biofilm formation. Subinhibitory concentrations (subminimum inhibitory concentrations) of the antibiotic dicloxacillin also affect the growth of S. haemolyticus biofilms. Biofilms formed in the presence of subinhibitory concentrations of dicloxacillin contain less biomass and have an altered composition. They are thinner, cover less surface area, and are less hydrophobic, but they also have an increased level of resistance to dicloxacillin.
http://aem.asm.org/content/79/16/5023.long He, Hongzhen; Ding, Yi; Bartlam, Mark; Sun, Fei; Le, Yi; Qin, Xincheng; Tang, Hong; Zhang, Rongguang; Joachimiak, Andrzej; Liu, Jinyuan; Zhao, Nanming; Rao, Zihe (2003). "Crystal Structure of Tabtoxin Resistance Protein Complexed with Acetyl Coenzyme A Reveals the Mechanism for β-Lactam Acetylation". Journal of Molecular Biology. 325 (5): 1019–1030. doi:10.1016/S0022-2836(02)01284-6. PMID 12527305.
Cold Mountain is an American opera in two acts and an epilogue, with music by Jennifer Higdon and the libretto by Gene Scheer, based on Charles Frazier's 1997 novel of the same name. The opera is a co-commission among Santa Fe Opera, Opera Philadelphia and the Minnesota Opera, in collaboration with North Carolina Opera. The opera received its world premiere at Santa Fe Opera on 1 August 2015. This production coincided with the 150th anniversary of the ending of the American Civil War. Opera Philadelphia gave its first performance of the opera, in a slightly revised form, on 5 February 2016. North Carolina Opera gave the opera its home state premiere on 28 September 2017. The Minnesota Opera staged the opera in 2018 as part of its New Works Initiative. The Virginia Opera also featured performances of the opera during February 2021 as part of its themed "Love is a Battlefield" 2020–2021 season.
=== Legal status === 1P-LSD is unscheduled in the United States and Canada, but may be considered illegal if sold or used for human consumption as an analogue of LSD under the Federal Analogue Act in the United States. 1P-LSD is a prohibited or controlled substance in Australia, France, Finland, Denmark, Germany, Estonia, Japan, Latvia, Norway, Romania, Sweden, Switzerland, United Kingdom, Italy, Singapore, the Czech Republic, and Croatia. 1P-LSD has been illegal in Russia since 2017 as an LSD derivative.
== Campus == The hospital campus comprises three interconnected medical blocks. A helicopter pad is located on the roof of the tallest block. The newest block was completed in 2014. It was designed by K.ITO Architects & Engineers.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.